Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results

nt; Favrille's ability to obtain additional financing to support its operations; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.


(a development stage company)


(in thousands, except share and per share data)

December 31,

2007 2006



Current assets:

Cash and cash equivalents $26,362 $14,249

Short-term investments 3,577 28,160

Other current assets 806 850

Total current assets 30,745 43,259

Property and equipment, net 33,293 25,071

Restricted cash 3,451 3,451

Other assets 466 508

Total assets $67,955 $72,289

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued liabilities $3,551 $6,779


SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... ® brand within its Applied Diagnostics and ... acid reference standards product line with ten certified ... tested bile acids and their stable-labeled internal standards. ... of lithocholic acid, taurocholic acid and native and ...
(Date:10/8/2015)... ... 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), announced ... commercialize intellectual property rights belonging to The University of British Columbia (UBC). This ... worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications ...
(Date:10/7/2015)... India , October 8, 2015 /PRNewswire/ ... --> Medical biotechnology accounts for largest ... of bioinformatics in drug discovery and development ... . ... On the basis of applications, the ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
Breaking Biology Technology:
... HARBIN, China , May 12 ... One Medical" or "the Company") (Nasdaq: CSKI ), ... Republic of China ,("PRC"), today provided an update on ... additional market research and customer feedback, the,Company estimates aggregate ...
... May 12 Sagent Pharmaceuticals, Inc., ... FDA approval of bacitracin for injection, USP (bacitracin), ... empyema. Bacitracin will be offered in a 50,000 ... individually and in packages of ten.  These vials ...
... , May 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... will present at the Rodman & Renshaw Annual Global Investment Conference taking place ... , , ... British Summer Time ( 5:15 a.m. Eastern Daylight Time ) on Tuesday, ...
Cached Biology Technology:
(Date:9/2/2015)... 2015 Security of data and assets ... government organizations, telecommunications, hospitals, as well as individuals. ... being used to prevent unauthorised access. Technological advancements ... individuals could gain access to secure premises after ... hardware devices and numeric codes. However, hackers also ...
(Date:9/1/2015)... 1, 2015  Automation and pre-processing are reducing ... screening. This is the first step toward a ... become unintrusive. An assortment of portal scanners, biometric ... investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( ...
(Date:8/31/2015)... Research and Markets ( ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Arabia Biomedical Sensors market is estimated at $0.23 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):
... Amyloid-beta and tau protein deposits in the brain are ... hippocampus, the area of the brain that plays a ... However, it appears that the toxic effect of tau ... is switched off. Researchers from the Max Planck Research ...
... Israel,s Wolf Foundation, whose stated mission is "to promote ... named Whitehead Institute Founding Member Rudolf Jaenisch a recipient ... Jaenisch will share this year,s prize with Kyoto University,s ... "their groundbreaking contribution to stem cell research." ...
... Jan. 12, 2011 The agreement grants DSM ... and secures supply of Codexis enzymes for commercialization ... DSM,s InnoSyn™ route scouting services. Codexis ... for active pharmaceutical ingredients and intermediates which reduce ...
Cached Biology News:
... comprehensive epitope analysis service utilizing high ... microfluidic chips for immunological studies, vaccine ... service includes assistance with your sequence ... by you, single or dual color ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. Thousands of customer specified ... LC Sciences can provide assistance with custom ... part of our comprehensive DNA/RNA Aptamer Microarray ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
Biology Products: